Sino Biological,Inc. (SHE:301047)
China
· Delayed Price · Currency is CNY 70.94
+0.84 (1.20%)
At close: Apr 29, 2026
Sino Biological,Inc. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2018 |
| Operating Revenue | 671.3 | 587.29 | 630.95 | 574.6 | 965.27 | Upgrade
|
| Other Revenue | 28.27 | 26.38 | 15.44 | - | - | Upgrade
|
| Revenue | 699.56 | 613.67 | 646.39 | 574.6 | 965.27 | Upgrade
|
| Revenue Growth (YoY) | 14.00% | -5.06% | 12.49% | -40.47% | -39.53% | Upgrade
|
| Cost of Revenue | 190.48 | 170.98 | 125.85 | 95.01 | 68.98 | Upgrade
|
| Gross Profit | 509.09 | 442.69 | 520.54 | 479.59 | 896.29 | Upgrade
|
| Selling, General & Admin | 310.79 | 305.19 | 280.26 | 207.29 | 141.48 | Upgrade
|
| Research & Development | 86.22 | 91.21 | 87.45 | 60.15 | 40.13 | Upgrade
|
| Other Operating Expenses | 14.98 | 8.74 | 6.03 | 8.36 | 13.45 | Upgrade
|
| Operating Expenses | 418.88 | 413.4 | 384.78 | 276.06 | 199.74 | Upgrade
|
| Operating Income | 90.21 | 29.29 | 135.76 | 203.53 | 696.56 | Upgrade
|
| Interest Expense | -3.09 | -3.98 | -3.73 | -2.77 | -2.01 | Upgrade
|
| Interest & Investment Income | 67.47 | 103.6 | 136.28 | 129.49 | 54.58 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.44 | -1.6 | 1.84 | 12.05 | -8.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.32 | -0.62 | -0.45 | -0.4 | -0.63 | Upgrade
|
| EBT Excluding Unusual Items | 150.84 | 126.7 | 269.71 | 341.9 | 740.43 | Upgrade
|
| Gain (Loss) on Sale of Investments | 24.63 | 4.88 | 10.98 | -14.38 | 34.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.54 | -0.35 | 0.05 | 0.21 | -0.01 | Upgrade
|
| Other Unusual Items | 3.54 | 10.1 | 7.21 | 14.78 | 70.89 | Upgrade
|
| Pretax Income | 179.54 | 141.33 | 287.95 | 342.51 | 845.45 | Upgrade
|
| Income Tax Expense | 31.8 | 19.41 | 27.82 | 39.55 | 125.44 | Upgrade
|
| Net Income | 147.74 | 121.93 | 260.13 | 302.96 | 720.01 | Upgrade
|
| Net Income to Common | 147.74 | 121.93 | 260.13 | 302.96 | 720.01 | Upgrade
|
| Net Income Growth | 21.17% | -53.13% | -14.14% | -57.92% | -36.15% | Upgrade
|
| Shares Outstanding (Basic) | 122 | 128 | 129 | 114 | 108 | Upgrade
|
| Shares Outstanding (Diluted) | 122 | 128 | 129 | 114 | 108 | Upgrade
|
| Shares Change (YoY) | -4.93% | -0.97% | 13.44% | 5.79% | 11.11% | Upgrade
|
| EPS (Basic) | 1.21 | 0.95 | 2.01 | 2.66 | 6.69 | Upgrade
|
| EPS (Diluted) | 1.21 | 0.95 | 2.01 | 2.66 | 6.69 | Upgrade
|
| EPS Growth | 27.45% | -52.67% | -24.30% | -60.22% | -42.53% | Upgrade
|
| Free Cash Flow | 45.14 | 43.78 | -720.8 | 93.34 | 594.72 | Upgrade
|
| Free Cash Flow Per Share | 0.37 | 0.34 | -5.58 | 0.82 | 5.52 | Upgrade
|
| Dividend Per Share | 5.200 | 1.000 | 2.000 | 2.000 | 5.263 | Upgrade
|
| Dividend Growth | 420.00% | -50.00% | - | -62.00% | - | Upgrade
|
| Gross Margin | 72.77% | 72.14% | 80.53% | 83.47% | 92.85% | Upgrade
|
| Operating Margin | 12.90% | 4.77% | 21.00% | 35.42% | 72.16% | Upgrade
|
| Profit Margin | 21.12% | 19.87% | 40.24% | 52.73% | 74.59% | Upgrade
|
| Free Cash Flow Margin | 6.45% | 7.13% | -111.51% | 16.24% | 61.61% | Upgrade
|
| EBITDA | 155.34 | 94.72 | 182.03 | 221.27 | 708.9 | Upgrade
|
| EBITDA Margin | 22.20% | 15.44% | 28.16% | 38.51% | 73.44% | Upgrade
|
| D&A For EBITDA | 65.13 | 65.43 | 46.26 | 17.74 | 12.35 | Upgrade
|
| EBIT | 90.21 | 29.29 | 135.76 | 203.53 | 696.56 | Upgrade
|
| EBIT Margin | 12.90% | 4.77% | 21.00% | 35.42% | 72.16% | Upgrade
|
| Effective Tax Rate | 17.71% | 13.73% | 9.66% | 11.55% | 14.84% | Upgrade
|
| Revenue as Reported | 699.56 | 613.67 | 646.39 | 574.6 | 965.27 | Upgrade
|
| Advertising Expenses | 23.53 | 28.18 | 34.43 | 36.95 | 25.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.